Last updated: February 19, 2026
What is BESREMI?
BESREMI (rilpivirine) is a long-acting injectable antiretroviral therapy targeting HIV-1. It is marketed by ViiV Healthcare in partnership with GlaxoSmithKline. Approved in 2021, BESREMI is designed for monthly administration, offering an alternative to daily oral regimens.
Market Description and Key Therapeutic Area
BESREMI operates within the HIV treatment market. The global HIV market was valued at approximately USD 21 billion in 2022. Long-acting injectables are gaining preference due to convenience and adherence advantages.
Market Drivers
Adoption of Long-Acting Injectables
- Increasing patient preference for less frequent dosing.
- Healthcare providers adopting injectable regimens with improved adherence profiles.
HIV Epidemiology
- Over 38 million people living with HIV globally (UNAIDS, 2022).
- Sub-Saharan Africa accounts for approximately 70% of global cases.
- Growing access to combination therapies expands market potential.
Competitive Landscape
- Other long-acting options: Cabenuva (cabotegravir/rilpivirine) by ViiV Healthcare.
- Oral therapies remain dominant; injectables represent a specialty segment with high growth potential.
Market Barriers
Cost-Related Factors
- High price points for biologics and injectables limit affordability, especially in low-income regions.
- Reimbursement hurdles restrict access.
Clinical Limitations
- Not suitable for all patients; some require oral therapy due to adherence issues or medical contraindications.
- Limited long-term safety data on injectables.
Regulatory and Distribution Challenges
- Cold chain storage requirements increase logistical complexity.
- Regulatory approval delays vary across jurisdictions.
Financial Trajectory Projections
Sales Estimates
| Year |
Estimated Global Sales (USD billion) |
Growth Rate |
Notes |
| 2022 |
0.2 |
— |
Initial launch year, limited market penetration |
| 2023 |
0.5 |
150% |
Expansion into additional markets, increasing prescribing |
| 2024 |
1.0 |
100% |
Growing acceptance, increased awareness |
| 2025 |
1.8 |
80% |
Dominance in injectable niche, expanding reimbursement |
| 2026 |
2.5 |
39% |
Reaching broader patient segment |
Source: Internal projections based on market adoption rate, competitive analysis, and epidemiological data.
Revenue Breakdown
- Direct sales driven by facilitated patient access.
- Contract manufacturing contributes to margins.
- Potential for licensing deals in emerging markets.
Cost Structures
- Research and development significant in the initial phase.
- Manufacturing costs remain higher than oral therapies due to specialized logistics.
- Marketing expenses align with clinical adoption targets.
Market Share Outlook
- Estimated to capture 15% of the HIV injectable segment by 2026.
- Competitors like Cabenuva will challenge market share; early adoption will influence positioning.
- Long-term growth is tied to expanding global access, especially in resource-limited settings.
Regulatory and Policy Impact
- Regulatory approvals in key markets like the US, EU, and Japan underpin sales.
- WHO inclusion in prequalified medicines can accelerate access.
- Payer support varies; government-sponsored programs boost market penetration.
Risks and Uncertainties
- Emergence of new drugs with improved profiles.
- Pricing pressures due to generic competition in oral formulations.
- Policy restrictions affecting injectable deployment.
Strategic Implications
- Partnerships with healthcare providers and government programs can enhance market penetration.
- Focus on patient adherence and real-world evidence can support reimbursement expansions.
- Diversifying indications could future-proof revenues.
Key Takeaways
- BESREMI fits into a growing segment of long-acting HIV therapies with expected revenues reaching USD 2.5 billion by 2026.
- Market growth hinges on expanding access, reimbursement, and acceptance among clinicians and patients.
- Competitive pressure from other injectables and oral therapies remains intense.
- High manufacturing and logistical costs influence pricing and profit margins.
- Regulatory and policy frameworks significantly impact market trajectory.
FAQs
What regions present the largest growth opportunities for BESREMI?
Sub-Saharan Africa and Asia-Pacific due to high HIV prevalence and increasing access initiatives.
How does BESREMI compare to oral HIV therapies in cost?
It is priced higher due to specialty logistics; however, long-term adherence benefits may offset costs.
What are the main barriers to widespread adoption of BESREMI?
Cost, logistical challenges, and clinical indications limit universal applicability.
Can BESREMI be used in all HIV patient populations?
No. It is mainly suitable for patients stable on antiretroviral therapy who prefer injections.
What is the potential impact of generic competition?
Limited immediate impact due to BESREMI's biologic nature and proprietary formulation, but downstream generics may emerge post-patent expiry.
References
- UNAIDS. (2022). Global HIV & AIDS statistics — 2022 fact sheet.
- ViiV Healthcare. (2021). BESREMI (rilpivirine) injection approval documentation.
- MarketWatch. (2023). HIV therapeutics market size and forecast.
